New drug shows promise in stroke recovery trial

NCT ID NCT07196605

First seen Sep 30, 2025 · Last updated Jun 22, 2026 · Updated 37 times

Summary

This study tested whether adding sodium sivelestat, a drug that reduces inflammation, to standard mechanical thrombectomy could improve outcomes in 20 stroke patients with large vessel occlusion. The drug aims to prevent 'futile recanalization,' where blood flow is restored but patients still do poorly. Results are expected to provide early evidence for a new anti-inflammatory approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Xuanwu Hospital, Capital Medical University.

    Beijing, 100053, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sodium sivelestat

What this could lead to

If it works, this could point toward a new anti-inflammatory treatment to improve recovery after stroke thrombectomy.

What could go wrong

This is a very small, early exploratory study with only 20 patients and no comparison group, so results may not be reliable or generalizable.

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke large artery stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.